Skip Navigation


Rheumatology Advance Access originally published online on August 11, 2009
Rheumatology 2009 48(10):1279-1282; doi:10.1093/rheumatology/kep228
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/10/1279    most recent
kep228v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nakayamada, S.
Right arrow Articles by Tanaka, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakayamada, S.
Right arrow Articles by Tanaka, Y.
Related Collections
Right arrow Sjogren's Syndrome
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Usefulness of initial histological features for stratifying Sjögren's syndrome responders to mizoribine therapy

Shingo Nakayamada1, Takashi Fujimoto2, Akitaka Nonomura3, Kazuyoshi Saito1, Shinobu Nakamura2 and Yoshiya Tanaka1

1The First Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, 2Department of General Medicine and 3Department of Diagnostic Pathology, Nara Medical University, School of Medicine, Kashihara, Japan.

Correspondence to: Yoshiya Tanaka, First Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. E-mail: tanaka{at}med.uoeh-u.ac.jp


  Abstract

Objectives. To evaluate the response of patients with SS to mizoribine therapy in relation to histological features of minor salivary glands.

Methods. Forty patients definitely diagnosed as having SS were treated with mizoribine (150 mg/day). Thirty-four untreated patients matched for age, baseline salivary secretion, etc., served as controls. Salivary secretion volume (measured by the Saxon test) and serum IgG level were measured before and after 24 weeks of treatment. Each histological finding (lymphocytic infiltration, acinar atrophy and intralobular fibrosis) was graded at baseline and the therapeutic responses were compared with the grade at 24 weeks in both the groups.

Results. There was a significant increase of the salivary secretion volume after treatment with mizoribine as compared with the untreated control group. The effect of mizoribine on salivary secretion was more marked in patients having moderate lymphocytic infiltration and moderate or less severe acinar atrophy and intralobular fibrosis at baseline.

Conclusions. Mizoribine was clinically effective in patients with SS whose minor salivary glands had moderate cell infiltration and were free of intralobular fibrosis. The drug was less effective in patients who presented intralobular fibrosis. Histological evaluation of the minor salivary glands may serve to predict the response of SS patients to mizoribine therapy.

KEY WORDS: Sjögren's syndrome, Mizoribine, Xerostomia, Salivary gland biopsy

Submitted 14 April 2009; revised version accepted 30 June 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.